<DOC>
	<DOCNO>NCT02313727</DOCNO>
	<brief_summary>It pilot , 2 year , prospective , randomize , double-blind , placebo-controlled ( pamidronate ) study . All patient AS receive treatment TNF inhibitor , randomization perform pamidronate versus placebo group . Primary outcome rate radiographic progression AS , calculate 24 month combine treatment .</brief_summary>
	<brief_title>Combined Treatment With TNF Inhibitor Pamidronate AS Patients : Effect Radiographic Progression</brief_title>
	<detailed_description>It pilot , 2 year , prospective , randomize , double-blind , placebo-controlled ( pamidronate ) study . All patient AS receive treatment tumor necrosis factor ( TNF ) inhibitor , indicate local guideline . Randomization perform pamidronate v placebo group . Pamidronate prescribe monthly intravenous infusion dose 60 mg/month first 6 consecutive month every study year . Primary outcome rate radiographic progression ankylose spondylitis ( AS ) , calculate 24 month combine treatment . Clinical laboratory disease parameter serve secondary outcome . These outcomes well safety assessment perform monthly basis 24 month .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>presence spinal syndesmophytes normal renal liver function eligibility receive antiTNF treatment accord local guideline unwilling sigh informed consent presence significant systemic organlimited disorder , AS contraindication antiTNF pamidronate treatment presence acute dental/periodontal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>